Press Room

Press Release / Dec 22, 2023

Hovione awarded prestigious industry medal by Macau Government

Hovione was recently awarded the Medal for Industrial and Commercial Merit by the Macau Government. Hovione started its manufacturing operations in Macau in 1986, producing lifesaving off-patent pharmaceutical actives for the world.

Hovione_Macau_Medal_for_Industrial_and_Commercial_Merit

22 December, 2023, Hovione is delighted to announce that the Hovione Macau site has been awarded the Medal for Industrial and Commercial Merit by the Government of Macau, a Special Administrative Region of the People´s Republic of China.

The site underwent its first of many successful FDA inspections in 1987 and ever since has produced off-patent pharmaceutical actives, which are sold in the global market and boost Macau´s exports. With 180 employees, it is the largest pharmaceutical site in Macau.

Over the years, Hovione has worked with a range of governmental departments to support the development of the pharmaceutical industry in Macau. This includes collaborating with the Macau Labor Affairs Bureau to develop the local workforce and create careers in the pharmaceutical industry. Hovione also works with the Education and Youth Development Bureau to organize visits from schools and universities and to arrange internships within the company for students. Team members are also invited by Macau University to give lectures on good manufacturing practice (GMP) and chemical analysis.

Eddy Leong, Site Manager of Hovione Macau said: “It is our great honor to receive this Medal of Merit. We would like to express our gratitude to the Macau SAR Government and all sectors of society for recognizing the company's nearly 40 years of presence and industrial activity in Macau. At Hovione, our motto is “In it for life” and this award not only reflects our long and successful history in Macau, but also points to our successful future here. It also reflects our commitment to work with partner organizations to create rewarding career opportunities in life sciences.”

The Medals of Merit cover seven categories (Industrial and Commercial, Tourism, Education, Culture, Altruism and Sports). They are intended to reward individuals or organizations that stand out in the exercise of their professional activity.

 

About Hovione:
Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. 

Hovione's culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024